DalsnaFinance

Arcturus Therapeutics Holdings Inc $ARCT

Health Care

Russell 2000 California
Create a scorecard
$10.73
-0.34 (-3.07%)
As of Oct 22, 2026, 9:30 PM EDT · cached
Price history
Loading chart…

Arcturus Therapeutics Holdings Inc (ARCT) is trading down at $10.73 (-3.07%), as of the latest quote. It is a Russell 2000 constituent in the Health Care sector.

Arcturus Therapeutics Holdings Inc revenue & net income history (FY2018–FY2025)

RevenueNet incomeNet margin (right axis, %)
$206.0M$1.16M−$203.7MFY2018 revenue: $15.8MFY2018 net income: −$21.8M · Net margin −138.3%'18FY2019 revenue: $20.8MFY2019 net income: −$26.0M · Net margin −125.0%'19FY2020 revenue: $9.54MFY2020 net income: −$72.1M · Net margin −756.3%'20FY2021 revenue: $12.4MFY2021 net income: −$203.7M · Net margin −1648.0%'21FY2022 revenue: $206.0MFY2022 net income: $9.35M · Net margin 4.5%'22FY2023 revenue: $166.8MFY2023 net income: −$29.7M · Net margin −17.8%'23FY2024 revenue: $152.3MFY2024 net income: −$80.9M · Net margin −53.1%'24FY2025 revenue: $82.0MFY2025 net income: −$65.8M · Net margin −80.2%'25−19.8%−10%0%10%20%FY2018 net margin: −138.3% (off the scale, which stops at −19.8%)FY2019 net margin: −125.0% (off the scale, which stops at −19.8%)FY2020 net margin: −756.3% (off the scale, which stops at −19.8%)FY2021 net margin: −1648.0% (off the scale, which stops at −19.8%)FY2022 net margin: 4.5%FY2023 net margin: −17.8%FY2024 net margin: −53.1% (off the scale, which stops at −19.8%)FY2025 net margin: −80.2% (off the scale, which stops at −19.8%)
Arcturus Therapeutics Holdings Inc annual financial statements
FY2018Dec 2018FY2019Dec 2019FY2020Dec 2020FY2021Dec 2021FY2022Dec 2022FY2023Dec 2023FY2024Dec 2024FY2025Dec 2025
Income statement
Revenue$15.8M$20.8M$9.54M$12.4M$206.0M$166.8M$152.3M$82.0M
Growth (year over year)—+32.0%−54.1%+29.6%+1566.8%−19.0%−8.7%−46.1%
Operating income−$21.8M−$25.5M−$71.5M−$202.9M$12.2M−$78.2M−$95.7M−$76.3M
Operating margin−138.5%−122.7%−749.8%−1641.3%5.9%−46.9%−62.8%−93.0%
Net income−$21.8M−$26.0M−$72.1M−$203.7M$9.35M−$29.7M−$80.9M−$65.8M
Net margin−138.3%−125.0%−756.3%−1648.0%4.5%−17.8%−53.1%−80.2%
EPS (diluted)−$2.16−$2.15−$3.55−$7.74$0.35−$1.12−$3.00−$2.40
Balance sheet
Cash and equivalents$36.7M$71.4M$462.9M$370.5M$391.9M$292.0M$237.0M$230.9M
Total assets$44.2M$82.1M$476.5M$392.8M$450.4M$429.4M$344.1M$271.1M
Total liabilities$30.6M$56.4M$79.9M$164.6M$180.1M$150.9M$103.1M$57.2M
Long-term debt$9.91M$15.0M$13.8M$40.6M————
Shareholders' equity$13.6M$25.8M$396.6M$228.2M$270.3M$278.5M$241.0M$214.0M
Cash flow
Operating cash flow−$20.8M−$6.45M−$42.9M−$135.0M$32.0M−$18.1M−$59.7M−$74.3M
Capital expenditure$1.48M$818.0K$1.74M$3.41M$7.73M$2.90M$648.0K$230.0K
Free cash flow−$22.2M−$7.26M−$44.6M−$138.4M$24.3M−$21.0M−$60.4M−$74.5M

From Arcturus Therapeutics Holdings Inc's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →

About Arcturus Therapeutics Holdings Inc

Headquarters
San Diego, California From SEC filings, Oct 2026

Recent News (1)

More Health Care stocks

Browse all companies →